Larimar Therapeutics, Inc. Profile Avatar - Palmy Investing

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical tria…

Biotechnology
US, Bala Cynwyd [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of LRMR's Analysis
CIK: 1374690 CUSIP: 517125100 ISIN: US5171251003 LEI: - UEI: -
Secondary Listings
LRMR has no secondary listings inside our databases.